Altium Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Immunovantimmunovant.cominJan 2025
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
BiotechHealthtechMedical DevicesNew York, US
Christopher Van Tuyl(Executive Officer)Michael Geffner(Executive Officer)inPete Salzmann(Executive Officer, Director)inJay Stout(Executive Officer)inMelanie Gloria(Executive Officer)inEva Renee Barnett(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.